Redhill Biopharma earnings were -$8.3M for the trailing 12 months ending Dec 31, 2024, with -100% growth year over year. The latest RDHL earnings report on Dec 31, 2024 announced Q4 2024 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RDHL reported annual earnings of -$8.3M, with -134.6% growth.
RDHL past earnings growth
How has RDHL's earnings growth performed historically?
What were Redhill Biopharma's earnings last quarter?
Redhill Biopharma (NASDAQ: RDHL) reported Q4 2024 earnings per share (EPS) of N/A, up N/A year over year. Total RDHL earnings for the quarter were N/A. In the same quarter last year, Redhill Biopharma's earnings per share (EPS) was N/A.
As of the last Redhill Biopharma earnings report, Redhill Biopharma is currently losing money. Redhill Biopharma's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$8.27 million, a 134.57% decrease year over year.
What was RDHL's earnings growth in the past year?
As of Redhill Biopharma's earnings date in Q2 2025, Redhill Biopharma's earnings has grown -100% year over year. This is 155.07 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 55.07%. RDHL earnings in the past year totalled -$8.27 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.